BLLSF (BioLight Life Sciences) Cyclically Adjusted PB Ratio: (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BLLSF BioLight Life Sciences Ltd BLLSF
16 GF Score
Price $0.09
! 3 Warning Signs
View Full Analysis

What is BioLight Life Sciences Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


BioLight Life Sciences  (GREY:BLLSF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


BioLight Life Sciences Cyclically Adjusted PB Ratio Related Terms


BioLight Life Sciences Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for BioLight Life Sciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioLight Life Sciences Cyclically Adjusted PB Ratio Chart

BioLight Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.08 0.10 0.10 0.32

BioLight Life Sciences Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.00 0.10 0.00 0.32

BLLSF vs VRTX, REGN, RVMD: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, BioLight Life Sciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLight Life Sciences Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLight Life Sciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where BioLight Life Sciences's Cyclically Adjusted PB Ratio falls into.


BLLSF
16GF Score
BioLight Life Sciences Ltd BLLSF
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioLight Life Sciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

BioLight Life Sciences's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec25 is calculated as:

For example, BioLight Life Sciences's adjusted Book Value per Share data for the fiscal year that ended in Dec25 was:

Adj_Book=Book Value per Share/CPI of Dec25 (Change)*Current CPI (Dec25)
=1.255/324.0540*324.0540
=1.255

Current CPI (Dec25) = 324.0540.

BioLight Life Sciences Annual Data

Book Value per Share CPI Adj_Book
201612 1.326 241.432 1.780
201712 0.553 246.524 0.727
201812 5.981 251.233 7.715
201912 5.002 256.974 6.308
202012 4.302 260.474 5.352
202112 4.393 278.802 5.106
202212 3.835 296.797 4.187
202312 2.110 306.746 2.229
202412 1.904 315.605 1.955
202512 1.255 324.054 1.255

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BioLight Life Sciences Business Description

Other Exchanges BOLT:Israel
Address Aba Hillel Silver 12, 11 floor, Ramat Gan, ISR, 5250606
BioLight Life Sciences Ltd is an emerging ophthalmic company. It is engaged in the discovery, development, and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, dry eye syndrome and age-related macular degeneration. The firm's products include ioptimate, eye-d technology, and diagnostear. The company has the Eye cluster and the Cancer diagnostics cluster operating segments. It derives the majority of its revenues from the Eye cluster segment.
16GF Score

Get the complete analysis for BLLSF

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.09
Price